10-K: Biogen's 2025 Performance: New Launches Offset MS Decline

Biogen reports 2.2% revenue growth in 2025 driven by new rare disease and neuropsychiatry launches, despite continued decline in MS product sales and increased R&D investments.

Summary

• Total revenue increased by $214.7 million (2.2%) to $9,890.6 million in 2025, compared to $9,675.9 million in 2024.
• Net income decreased by $339.3 million (20.8%) to $1,292.9 million in 2025, down from $1,632.2 million in 2024.
• Diluted earnings per share decreased by $2.39 (21.4%) to $8.79 in 2025, from $11.18 in 2024.
• Product revenue, net, decreased by $94.1 million (1.3%) to $7,119.4 million in 2025.
• Multiple Sclerosis (MS) revenue decreased by $310.9 million (7.1%) to $4,038.9 million, primarily due to increased global competition for TECFIDERA and TYSABRI.
• Rare disease revenue increased by $166.1 million (8.4%) to $2,154.2 million, driven by new product launches, including global SKYCLARYS revenue of $520.5 million and global QALSODY revenue of $86.9 million.
• ZURZUVAE revenue increased by $122.9 million (170.2%) to $195.1 million in 2025, driven by continued U.S. launch and increased patient demand.
• Acquired in-process research and development (IPR&D), upfront, and milestone expense increased by $410.3 million to $471.8 million in 2025.
• Research and development (R&D) expense decreased by $201.7 million (10.2%) to $1,778.6 million, primarily due to cost reduction measures, partially offset by higher clinical trial spend for litifilimab and felzartamab.
• Selling, general and administrative (SG&A) expense increased by $29.9 million (1.2%) to $2,433.6 million, due to increased sales and marketing activities for LEQEMBI and SKYCLARYS launches.
• Cash, cash equivalents, and marketable securities totaled approximately $4.2 billion as of December 31, 2025, up from $2.4 billion as of December 31, 2024.
• Net cash flow from operations decreased to $2.2 billion in 2025, from $2.9 billion in 2024, partly due to higher worldwide tax payments of approximately $864.0 million in 2025.
• Issued senior unsecured notes for an aggregate principal amount of $1.75 billion in May 2025, with proceeds used to redeem $1.75 billion of 4.050% Senior Notes due September 2025.
• Recorded an impairment charge of approximately $52.9 million related to the Reata lease in 2025.
• Incurred $139.5 million in litigation-related expense in 2025, including an agreement in principle to resolve claims related to the Convergence acquisition.
• The Inflation Reduction Act (IRA) Medicare Part D redesign had a net unfavorable impact of approximately $90.0 million on 2025 revenue, concentrated in SKYCLARYS and the MS portfolio.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative report. While new product launches show promise and strategic acquisitions are expanding the pipeline, the significant declines in net income, EPS, and operating cash flow, coupled with ongoing revenue erosion in the core MS business and substantial litigation/impairment charges, indicate considerable headwinds. The long-term outlook depends heavily on successful pipeline execution and market acceptance of new therapies, which remains uncertain.

Positives

• Total revenue increased by 2.2% to $9,890.6 million in 2025.
• Rare disease product revenue increased by 8.4% to $2,154.2 million, driven by new product launches.
• Global SKYCLARYS revenue increased by 36.1% to $520.5 million in 2025.
• Global QALSODY revenue increased by 168.2% to $86.9 million in 2025.
• ZURZUVAE revenue increased by 170.2% to $195.1 million in 2025, driven by increased patient demand in the U.S.
• LEQEMBI received FDA approval for monthly IV maintenance dosing in January 2025 and for a subcutaneous autoinjector for weekly maintenance dosing in August 2025.
• LEQEMBI received multiple international approvals: MHRA (UK) in November 2025, Health Canada in October 2025, NMPA (China) in September 2025, Therapeutic Goods Administration (Australia) in September 2025, and EC in April 2025.
• ZURZUVAE was approved in the E.U. in September 2025 and granted marketing authorization in the U.K. in August 2025 for Postpartum Depression (PPD).
• Felzartamab initiated dosing in global Phase 3 PREVAIL (IgAN) and PROMINENT (PMN) studies in June 2025, and the global Phase 3 TRANSCEND (AMR) study in March 2025.
• SPINRAZA high dose regimen received marketing authorization in the E.U. in January 2026 and was approved in Japan in September 2025.
• QALSODY was approved by the MHRA (UK) in July 2025 and received conditional marketing authorization from Health Canada in March 2025 for SOD1 ALS.
• BIIB080, an investigational ASO therapy for Alzheimer's disease, was granted FDA Fast Track designation in April 2025.
• Completed the acquisition of Alcyone Therapeutics, Inc. in November 2025 for approximately $85.0 million, enhancing CNS drug delivery capabilities with ThecaFlex DRx.
• Entered into a research collaboration with Dayra Therapeutics in October 2025 with an upfront payment of $50.0 million to discover oral macrocyclic peptides for immunological conditions.
• Entered into a license agreement with Vanqua Bio in October 2025 with an upfront payment of $70.0 million for exclusive worldwide rights to a preclinical oral C5aR1 antagonist compound.
• Entered into a collaboration and license agreement with Stoke Therapeutics in February 2025 with an upfront payment of $165.0 million to co-develop zorevunersen for Dravet syndrome, with the first patient dosed in a global Phase 3 trial in August 2025.
• Received $200.0 million in 2025 from Royalty Pharma to co-fund development costs for the litifilimab program, with up to $50.0 million more expected in 2026.
• Positive interim topline results from the Phase 1b study of salanersen for SMA, with a Phase 3 registrational study expected to begin in 2026.
• Initiated dosing in the global Phase 3 BRAVE study of omaveloxolone in children with Friedreich Ataxia (FA) in June 2025.
• The 'Fit for Growth' cost-saving program generated approximately $1.0 billion in gross operating expense savings by the end of 2025.
• The Solothurn, Switzerland manufacturing facility is operational and approved for the manufacture of LEQEMBI and TYSABRI.
• A new clinical packaging and other manufacturing facility in Research Triangle Park (RTP), North Carolina, was completed and largely placed in service during 2025.

Negatives

• Net income decreased by 20.8% and diluted earnings per share decreased by 21.4% in 2025.
• Product revenue, net, decreased by 1.3% in 2025.
• Multiple Sclerosis (MS) revenue decreased by 7.1% due to increased generic competition for TECFIDERA and biosimilar competition for TYSABRI.
• Global TECFIDERA revenue decreased by 29.7% to $679.7 million due to generic entrants.
• Global TYSABRI revenue decreased by 2.9% to $1,665.4 million due to biosimilar competition.
• Global Interferon revenue decreased by 2.3% to $945.6 million, driven by patient transition to higher efficacy therapies.
• Rest of world SPINRAZA revenue decreased by 2.8% due to lower demand and unfavorable foreign currency exchange.
• Biosimilar revenue decreased by 8.1% to $729.1 million due to lower sales volumes, pricing pressure, and unfavorable foreign currency exchange.
• Discontinued further development of BIIB143 (cemdomespib) for Diabetic Painful Neuropathy (DPN) in early 2025.
• Discontinued the open label Phase 1b study of felzartamab for the treatment of lupus nephritis in November 2025.
• Completed the sale of regulatory and commercial rights for TOFIDENCE in the U.S. in March 2025, recognizing a de minimis loss.
• Completed the sale of remaining commercial rights to BYOOVIZ and OPUVIZ in Europe in October 2025.
• Net cash flow from operations decreased by 23.3% to $2.2 billion, partly due to lower net income and higher worldwide tax payments.
• Incurred $139.5 million in litigation-related expense in 2025, including a settlement agreement for the Convergence acquisition.
• Recorded an impairment charge of approximately $52.9 million related to the Reata lease in 2025.
• The FDA issued a Complete Response Letter (CRL) for the supplemental New Drug Application (NDA) for a higher dose regimen of SPINRAZA in September 2025, requesting an update to the Chemistry Manufacturing and Controls module.
• The European General Court annulled the May 2023 European Commission decision granting TECFIDERA an additional year of regulatory marketing protection in September 2025 (appeal pending).
• A German tax authority issued assessments against the company of approximately $246.5 million, including interest, in December 2025 and January 2026, which is being challenged.
• A court entered judgment against the company for approximately $124.3 million in November 2025 in Genentech litigation related to TYSABRI royalties (appeal pending).
• The IRA Medicare Part D redesign had a net unfavorable impact of approximately $90.0 million on 2025 revenue, concentrated in SKYCLARYS and the MS portfolio.

Risks

• Substantial dependence on revenue from existing products, which face increasing competition from new originator therapies, generics, prodrugs, and biosimilars, potentially leading to significant price and volume reductions.
• Uncertainty in the successful commercialization of LEQEMBI and SKYCLARYS due to challenges in obtaining and maintaining adequate reimbursement, market acceptance, and competition from other new products.
• Long-term success depends on the successful development of new products and additional indications for existing products, which is an expensive, uncertain, and high-risk process with a low success rate.
• Clinical trial data are subject to differing interpretations by regulatory authorities, potentially leading to requirements for additional data, limited approvals, or outright denial of product candidates.
• Failure to compete effectively in the biopharmaceutical industry due to more efficacious, safer, less expensive, or more convenient alternatives, off-label use, patient dynamics, damage to confidence, or inability to maintain intellectual property.
• Risks associated with the execution and realization of anticipated benefits from strategic and growth initiatives, including acquisitions (Alcyone, HI-Bio, Reata) and cost-reduction programs (Fit for Growth).
• Inability to obtain and maintain adequate coverage, pricing, and reimbursement from government health administration authorities, private health insurers, and other organizations, which are under increasing pressure to control costs.
• Adverse effects from current and potential future healthcare reforms, including the IRA (drug price negotiation, inflation rebates, Medicare Part D redesign) and the OBBBA, which could significantly impact revenue and increase regulatory burdens.
• Inherent risks in the development, manufacture, and commercialization of biosimilars, including reliance on third parties, competitive challenges, regulatory hurdles, supply chain difficulties, intellectual property litigation, and failure to gain market acceptance.
• Inability to obtain and maintain adequate protection for data, intellectual property, and other proprietary rights, potentially leading to loss of exclusivity, inability to engage in certain activities, or payment of significant damages/royalties to third parties.
• Adverse safety events or restrictions on use and safety warnings for products, which could lead to product liability, additional regulatory scrutiny, market withdrawal, fines, or reputational damage.
• Breakdowns or breaches of information systems, including cloud technologies, could result in significant liability, business interruptions, unauthorized access to sensitive data (intellectual property, personal information), and cybersecurity incidents (e.g., ransomware, adversarial AI).
• Manufacturing issues, such as reliance on third-party/single-source providers, global bulk supply risks, non-compliance with cGMP, or product loss due to contamination or equipment failure, could increase costs, limit supply, or reduce revenue.
• Management, personnel, and other organizational changes may disrupt operations, and difficulty in attracting and retaining qualified personnel in a highly competitive environment could adversely affect the business.
• Failure to comply with extensive legal and regulatory requirements affecting the healthcare industry (e.g., anti-kickback, false claims, data privacy, foreign anti-corruption) could lead to increased costs, penalties, and loss of business.
• Risks of doing business internationally, including geopolitical tensions (Russia-Ukraine, Middle East), less favorable intellectual property laws, regulatory delays, pricing pressures, supply chain disruptions, and complex compliance requirements.
• Significant investment in manufacturing facilities (Solothurn, RTP) with no assurance that the additional capacity will be required or that the investment will be fully recouped, potentially leading to excess capacity charges.
• The illegal distribution and sale by third parties of counterfeit or unfit versions of products or stolen products could negatively impact reputation and business.
• The increasing use of social media platforms presents new risks and challenges, including noncompliance with regulations, adverse event reporting failures, and reputational damage from negative or inaccurate posts.
• Operating results are subject to significant fluctuations due to the timing of charges, R&D program terminations, impairments, inventory write-downs, fair value changes, litigation outcomes, and foreign currency exchange rate fluctuations.
• Investments in properties may not be fully realized, potentially leading to significant impairment charges or costs if facilities are vacated.
• Inability to access the capital and credit markets on favorable terms could increase financing costs.
• Indebtedness and significant contingent liabilities could increase vulnerability to adverse economic and industry conditions and limit financial flexibility.
• The investment portfolio is subject to market, interest, and credit risk that may reduce its value.
• No assurance that the company will repurchase shares or that repurchases will occur at favorable prices, potentially negatively affecting the stock price.
• Some collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire the company.
• The effective tax rate fluctuates, and the company may incur obligations in tax jurisdictions in excess of accrued amounts due to changes in tax laws (e.g., OBBBA, Pillar Two), audit results, and profitability mix.
• Business involves environmental and operational risks, including the cost of compliance with evolving regulations and the risk of contamination or injury from hazardous materials.

Future Outlook

Biogen anticipates a continued decline in total MS revenue in 2026 due to accelerating generic competition for TECFIDERA and biosimilar competition for TYSABRI, partially offset by increasing demand for VUMERITY. Growth in rare disease revenue is expected in 2026 from the continued launches of SKYCLARYS and QALSODY, while global SPINRAZA revenue is projected to be relatively flat. U.S. ZURZUVAE revenue is expected to grow with increasing patient numbers. Core R&D expense is forecast to increase slightly in 2026, focusing on late-stage programs, and SG&A expense is expected to remain relatively flat. The company anticipates lower net interest expense in 2026 due to higher cash balances. The Phase 3 registrational study of salanersen is expected to begin in 2026. The full impact of the IRA's drug pricing controls and Medicare Part D redesign, as well as the OBBBA, remains uncertain but is expected to adversely affect sales, particularly for Medicare-reliant products. Geopolitical tensions and potential new tariffs also pose ongoing uncertainties.

Management Comments

• "We believe our long-term competitive position depends upon our success in discovering and developing innovative, cost-effective products that serve unmet medical needs, along with our ability to manufacture products efficiently and to launch and market them effectively in a highly competitive environment."
• "We are dedicated to helping patients obtain access to our therapies."
• "We believe all healthcare stakeholders have a shared responsibility to ensure patients have equitable access to new, innovative medicines."
• "We regularly review our pricing strategy and prioritize patient access to our therapies."
• "We seek to ensure an uninterrupted supply of medicines to patients around the world."
• "Our Corporate Responsibility strategy and programs are designed to deliver meaningful results in the areas where we believe we can have the greatest impact."
• "Our Board of Directors believes that a fundamental part of risk management is identifying and understanding the risks we face, monitoring these risks and adopting appropriate controls and mitigation of such risks."
• "Our values and merit-based culture guide every action we take, from pioneering new therapies to promoting health access for all patients."
• "We care about employee feedback and are building an analytics community across Human Resources to bring more rigor and sophistication to the collection and analysis of employee opinions."
• "Our approach to employee compensation and benefits is designed to deliver merit-based cash, equity and benefit programs that are competitive with those offered by leading companies in the biotechnology industry, and to attract, motivate and retain talent to build a strong, engaged and productive workforce that is equipped to deliver forward-looking business priorities."
• "The safety and well-being of our employees is a priority for Biogen, and we believe every employee plays a role in creating a safe and healthy workplace."
• "We are committed to merit-based opportunities and believe discrimination is unacceptable. We believe an inclusive workplace fosters innovation and helps us to better support patients."

Industry Context

StockSavvy.ai notes that Biogen's strategic shift towards rare diseases and Alzheimer's, exemplified by the growth of SKYCLARYS, QALSODY, and LEQEMBI, aligns with a broader biopharmaceutical industry trend of focusing on high-unmet-need areas to offset revenue erosion from mature products facing generic and biosimilar competition. The significant R&D investment in late-stage programs like felzartamab and zorevunersen, coupled with strategic collaborations and acquisitions in specialized immunology and CNS, indicates a proactive approach to pipeline replenishment. However, the continued decline in the MS portfolio and the impact of healthcare reforms like the IRA highlight the persistent pricing pressures and competitive intensity across the sector. The company's efforts in biosimilars, while facing competitive challenges, also reflect a common strategy among large pharma to diversify revenue streams.

Comparison to Industry Standards

• Biogen's 2.2% total revenue growth is modest compared to high-growth biotech firms but reflects a challenging period of patent expirations and increased competition for its legacy MS portfolio.
• The 7.1% decline in MS revenue due to generic TECFIDERA and TYSABRI biosimilar competition is consistent with industry trends where originator biologics typically face significant revenue erosion post-exclusivity, often exceeding 50% within a few years, similar to the impact seen on Humira after biosimilar entry.
• The strong growth in new rare disease products like SKYCLARYS (36.1% increase) and QALSODY (168.2% increase) demonstrates successful market penetration in specialized areas, which often command premium pricing and face less immediate competition than broader therapeutic categories, comparable to the initial launch trajectories of other orphan drugs.
• The 170.2% increase in ZURZUVAE revenue for PPD indicates a successful launch in a novel therapeutic area, potentially outperforming initial market expectations for a first-in-class treatment.
• The $1.0 billion in gross operating expense savings from the 'Fit for Growth' program is a substantial cost-efficiency measure, reflecting a common industry response to revenue pressures and the need to reallocate resources to innovation.
• The R&D funding arrangement with Royalty Pharma for litifilimab is a strategic financing model increasingly adopted in the biotech sector to de-risk late-stage development and share costs, similar to deals seen with other large pharmaceutical companies seeking to optimize capital allocation.
• The FDA's Fast Track designation for BIIB080 (tau ASO for Alzheimer's) is a standard regulatory mechanism to expedite development for serious conditions with unmet needs, aligning with industry efforts to accelerate therapies for neurodegenerative diseases.

Management Changes

Corporate Governance

Legal Proceedings

• Three securities litigation actions are pending in the U.S. District Court for the District of Massachusetts (District Court) against Biogen and certain current/former officers, alleging federal securities law violations related to ADUHELM, LEQEMBI, TECFIDERA, and VUMERITY.
• Five derivative actions are pending in the District Court against Biogen and Board members, alleging breach of fiduciary duty, waste of corporate assets, and other claims related to ADUHELM, LEQEMBI, compliance controls, and 2023 earnings guidance (all stayed).
• In IMRALDI Patent Litigation, Fresenius Kabi filed a claim in France in June 2022 for damages and injunctive relief, alleging infringement of EP 3 145 488 Patent (trial set for June 2026). The Higher Regional Court of Düsseldorf, Germany, held in May 2025 that an IMRALDI formulation infringed the German counterpart of the patent, enjoining infringement and allowing damages claims (Biogen appealed).
• An agreement in principle has been reached to resolve all claims relating to Biogen's acquisition of Convergence, which included a $49.9 million claim.
• Humana filed suit in February 2025 alleging damages related to providing MS patients with free medications and charitable contributions.
• In Genentech Litigation, a court entered judgment against Biogen for approximately $124.3 million in November 2025 for royalties on TYSABRI sales after patent expiration (Biogen appealed).
• Lender Litigation filed in 2024 by BioPharma Credit PLC et al. was discontinued with prejudice in April 2025.
• Antitrust Litigation includes an amended complaint filed in October 2025 by Local No. 1 Health Fund et al. and a separate suit by Walgreen Co. and The Kroger Co. in September 2025, alleging federal antitrust law violations related to contracts with pharmacy benefit managers for TECFIDERA and VUMERITY.
• In Neurimmune Litigation, Biogen sued Neurimmune in May 2025 seeking declaratory judgment regarding rights under a terminated aducanumab collaboration, and Neurimmune counterclaimed in September 2025 for breach of contract and unfair competition.
• TECFIDERA E.U. Litigation involves lawsuits filed in the Netherlands (November 2023) and Denmark (June 2024) against generic manufacturers for damages related to TECFIDERA sales, with counterclaims for damages (cases stayed). The European General Court annulled the May 2023 EC decision granting TECFIDERA an additional year of regulatory marketing protection in September 2025 (appeal pending).
• A German tax authority issued assessments against the company of approximately $246.5 million, including interest, in December 2025 and January 2026, which the company is challenging.
• Government Investigations: SEC Division of Enforcement, DOJ, and SEC closed matters related to ADUHELM, equity plans, and foreign business operations in April/May 2025. The Italian Competition Authority is investigating BYOOVIZ (May 2024). A Civil Investigative Demand was received from the Louisiana Department of Justice regarding 340B drug purchases (September 2025).
• In TYSABRI Biosimilar Patent Matter, an action was filed against Sandoz Inc. et al. in September 2022 seeking a declaratory judgment of patent infringement, with trial scheduled for April 2027.
• Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents was settled in July 2025 with Zydus Worldwide DMCC et al.
• In the Eisai Matter, a request for arbitration was filed in June 2025 seeking adoption of a budget and commercialization plan for the European Territory for LEQEMBI.
• The company is involved in product liability claims and other legal proceedings incidental to normal business activities, which are not believed to have a material adverse effect.

Related Party Transactions

• Collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI, sharing costs, profits, and losses equally.
• Collaboration and license agreement with Supernus (previously Sage) to jointly develop and commercialize ZURZUVAE, sharing equal responsibility and costs for development and profits/losses for U.S. commercialization.
• Agreements with Genentech (Roche Group) entitling Biogen to certain business and financial rights for RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI, including tiered profit shares and royalties.
• Collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, sharing costs, profits, and losses equally for agreed indications.
• Several exclusive, worldwide option and collaboration agreements with Ionis Pharmaceuticals, Inc. to develop and commercialize antisense therapeutics, including SPINRAZA, QALSODY, salanersen (BIIB115), and BIIB080 (tau ASO), involving milestone payments and tiered royalties.
• Collaboration and license agreement with Denali Therapeutics Inc. to co-develop and co-commercialize BIIB122, sharing global development costs and U.S./China commercialization profits/losses, with potential tiered royalties outside these regions.
• Collaboration and license agreement with Stoke Therapeutics, Inc. to co-develop and commercialize zorevunersen, with Stoke leading global development and retaining U.S./Canada/Mexico rights, and Biogen having exclusive rights in the rest of the world, sharing external clinical development costs (Stoke 70%, Biogen 30%), and potential milestone payments and tiered royalties.
• Agreement with Samsung Bioepis Co., Ltd. to commercialize three anti-TNF biosimilar product candidates (BENEPALI, IMRALDI, FLIXABI) in certain European countries, sharing 50% of profits/losses. Also licenses proprietary technology to Samsung Bioepis for biosimilar development, manufacturing, and commercialization, receiving single-digit royalties.
• Funding agreement with Royalty Pharma to co-fund development costs for the litifilimab program, receiving $200.0 million in 2025 and up to $50.0 million in 2026, with potential approval-based milestone payments and mid-single digit royalties.
• Acquired HI-Bio's pre-existing in-license commitments under third-party agreements with MorphoSys, including tiered royalties and potential development, regulatory, and commercial milestone payments for felzartamab.
• Strategic research arrangement with City Therapeutics, Inc. to develop novel RNAi therapies, including a $16.0 million upfront payment and a $30.0 million investment in a convertible note, with potential research, development, and sales-based milestone payments and tiered royalties.
• Research collaboration with Dayra Therapeutics, Inc. to discover and develop oral macrocyclic peptides, with an upfront payment of $50.0 million and potential preclinical/clinical development milestone payments.
• License agreement with Vanqua Bio, Inc. for exclusive worldwide rights to a preclinical oral C5aR1 antagonist compound, with an upfront payment of $70.0 million and potential development, regulatory/commercial, and sales milestone payments, plus tiered royalties.
• Investment in a $5.0 million convertible note in Neela Therapeutics, Inc. during 2025.

Stakeholder Impact

• Shareholders: Impacted by decreased net income and EPS, ongoing share repurchase program, and potential volatility from litigation and market competition. New product launches and pipeline advancements offer future growth potential.
• Employees: Affected by the 'Fit for Growth' cost-saving program, which included net headcount reductions of approximately 1,400 employees by the end of 2025. Management changes and flexible work arrangements also impact the workforce. The company emphasizes culture, engagement, and competitive compensation/benefits.
• Customers/Patients: Benefit from new product approvals (LEQEMBI, ZURZUVAE, SKYCLARYS, QALSODY, SPINRAZA high dose) and pipeline advancements in neurology, immunology, and rare diseases. Access and affordability are influenced by drug pricing policies and reimbursement changes.
• Suppliers/Creditors: Affected by supply chain disruptions, geopolitical tensions, and the company's ability to access capital markets. Creditors are impacted by the company's debt obligations and refinancing activities.
• Regulatory Bodies: Engaged through numerous product approvals, clinical trial initiations, and ongoing compliance with evolving healthcare and data privacy regulations, including new climate-related disclosure requirements.

Next Steps

• FDA PDUFA action date for LEQEMBI subcutaneous autoinjector weekly starting dose on May 24, 2026.
• FDA PDUFA action date for SPINRAZA high dose regimen supplemental NDA on April 3, 2026.
• Phase 3 registrational study of salanersen is expected to begin in 2026.
• Royalty Pharma is expected to provide up to $50.0 million in 2026 to co-fund the litifilimab program.
• The final report for the LEQEMBI two-year real-world study in the U.S. is scheduled for late in the third quarter of Eisai's fiscal year ending March 31, 2026.
• The trial for IMRALDI Patent Litigation in France is set for June 2026.
• An appeal is pending for the $124.3 million judgment against the company in the Genentech litigation.
• The company is challenging the approximately $246.5 million in assessments issued by a German tax authority.
• An appeal is pending regarding the European General Court's annulment of the May 2023 EC decision on TECFIDERA marketing protection.
• The trial against Sandoz Inc. for the TYSABRI Biosimilar Patent Matter is scheduled for April 2027.
• Additional federal and state guidance is expected to be issued to implement OBBBA provisions, with most effective dates in 2027 and 2028.
• The initial lease term for the new corporate headquarters is expected to commence on May 31, 2028.
• SKYCLARYS inventory step-up amortization is expected to be fully amortized by the end of 2028.
• The supply agreement with Eisai to manufacture LEQEMBI drug substance and drug product extends through the end of 2031.
• The company will continue to monitor the global tariff landscape.
• The company will continue to monitor the ongoing conflicts in Russia-Ukraine and the Middle East and assess potential impacts.
• The company will evaluate the potential impact of the executive order aiming to establish a Most-Favored-Nation (MFN) drug pricing policy.
• The company expects to be subject to new E.U. and California climate disclosure laws.

Key Dates

Recommendation

Biogen is in a transitional phase, with declining revenue from its legacy MS portfolio being offset by promising new launches in rare diseases and Alzheimer's. While the pipeline shows potential and strategic acquisitions are expanding future growth avenues, the significant drop in net income and EPS, coupled with ongoing litigation and regulatory challenges, creates considerable uncertainty. The company's ability to execute on its 'Fit for Growth' program and successfully commercialize its new therapies will be critical. For a seasoned investor, a 'hold' recommendation is appropriate, awaiting clearer signs of sustained profitability and successful pipeline progression to outweigh the current headwinds and competitive pressures.

Keywords

Biopharmaceutical, Neurology, Rare Disease, Immunology, Alzheimer's Disease, Multiple Sclerosis, Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis, Dravet Syndrome, Friedreich Ataxia, Postpartum Depression, LEQEMBI, SKYCLARYS, SPINRAZA, QALSODY, ZURZUVAE, Felzartamab, Litifilimab, Zorevunersen, ASO, Biosimilars, SEC Filing, 10-K, Financial Results, Product Pipeline, Regulatory Approval, Clinical Trials, Acquisitions, Collaborations, Cost Savings, Healthcare Reform, Drug Pricing, Intellectual Property, Cybersecurity, Biogen